Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Am J Clin Nutr ; 84(1): 252-62, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16825703

ABSTRACT

BACKGROUND: Patients treated with hemodialysis frequently experience cardiovascular complications attributed, among other causes, to dyslipidemia, increased oxidative stress, and inflammation. OBJECTIVE: The aim of the study was to study the effects of dietary supplementation with concentrated red grape juice (RGJ), a source of polyphenols, on lipoprotein profile, antioxidant capacity, LDL oxidation, and inflammatory biomarkers. DESIGN: Twenty-six patients receiving hemodialysis and 15 healthy subjects were instructed to drink 100 mL RGJ/d for 14 d. Blood was drawn at baseline, twice during RGJ supplementation, and twice during the 6-mo follow-up period. As a control, 12 other randomly recruited hemodialysis patients not receiving RGJ were studied. Lipids, apolipoproteins, oxidized LDL, and antioxidant vitamins were measured in plasma. The bioavailability of RGJ polyphenols was assessed in healthy subjects. RESULTS: The maximum plasma concentration of quercetin was achieved 3 h after RGJ ingestion, which indicates that supplement-derived polyphenols are rapidly absorbed. In both healthy subjects and hemodialysis patients, RGJ consumption increased the antioxidant capacity of plasma without affecting concentrations of uric acid or ascorbic acid; reduced the concentration of oxidized LDL; and increased the concentration of cholesterol-standardized alpha-tocopherol. RGJ supplementation also caused a significant decrease in LDL-cholesterol and apolipoprotein B-100 concentrations, while increasing the concentrations of HDL cholesterol and apolipoprotein A-I. In a further study in hemodialysis patients, RGJ supplementation for 3 wk significantly reduced plasma monocyte chemoattractant protein 1, an inflammatory biomarker associated with cardiovascular disease risk. CONCLUSION: Dietary supplementation with concentrated RGJ improves the lipoprotein profile, reduces plasma concentrations of inflammatory biomarkers and oxidized LDL, and may favor a reduction in cardiovascular disease risk.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Beverages , Hypolipidemic Agents/pharmacology , Renal Dialysis , Vitis/chemistry , Adult , Biological Availability , Biomarkers/blood , Female , Flavonoids/metabolism , Flavonoids/pharmacokinetics , Humans , Intestinal Absorption , Kidney Failure, Chronic/metabolism , Kidney Failure, Chronic/therapy , Lipid Metabolism/drug effects , Lipids/blood , Male , Middle Aged , Oxidation-Reduction , Phenols/metabolism , Phenols/pharmacokinetics , Plant Extracts/pharmacology , Polyphenols , Quercetin/blood
3.
Am J Kidney Dis ; 41(4): 814-21, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12666068

ABSTRACT

BACKGROUND: The role of hypertension as a predictor of mortality in hemodialysis patients is controversial. The purpose of this study is to investigate the effect of hypertension before starting hemodialysis therapy on survival of patients without diabetes during renal replacement therapy. METHODS: We reviewed 184 patients starting hemodialysis therapy. Variables studied were age, sex, renal disease, hypertension, comorbidity, vascular calcifications, left ventricular hypertrophy, body mass index, and albumin, cholesterol, and alkaline phosphatase levels. Regarding blood pressure control, three groups were considered: normotensive (NH), controlled hypertensive (c-HT), and uncontrolled hypertensive (uc-HT). RESULTS: The Cox model was performed considering all-cause and cardiovascular mortality. The model was adjusted for age, sex, serum albumin level, vascular calcifications, history of hypertension, and comorbidity. Comorbidity included cardiovascular comorbidity. For all-cause mortality, comorbidity and history of uncontrolled hypertension were independent risk factors (comorbidity relative risk, 1.95; 95% confidence interval, 1.26 to 3.1; P = 0.003; uncontrolled hypertension relative risk, 1.79; 95% confidence interval, 1.15 to 2.8; P = 0.01). For cardiovascular mortality, uncontrolled hypertension was the main risk factor (relative risk, 2.93; 95% confidence interval, 1.68 to 5.12; P = 0.000). Mortality rates were 7.9/100 patient-years for NH, 8.7/100 patient-years for c-HT, and 14.1/100 patient-years for uc-HT patients. CONCLUSION: This study suggests that uncontrolled hypertension in renal patients before starting dialysis therapy is a major risk factor for cardiovascular mortality during hemodialysis. Because hypertension usually starts in the initial stages of renal disease, we emphasize the importance of prompt and adequate control of blood pressure in this population.


Subject(s)
Hypertension/epidemiology , Kidney Failure, Chronic/epidemiology , Mortality , Renal Dialysis , Adolescent , Adult , Aged , Cardiovascular Diseases/mortality , Comorbidity , Female , Follow-Up Studies , Gastrointestinal Diseases/mortality , Humans , Hypertension, Renal/epidemiology , Hypertrophy, Left Ventricular/epidemiology , Kidney Failure, Chronic/therapy , Life Tables , Lung Diseases/mortality , Male , Middle Aged , Neoplasms/mortality , Obesity/epidemiology , Proportional Hazards Models , Retrospective Studies , Risk Factors , Survival Analysis , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...